


CORRECTION

Open Access



# Correction to: White-coat hypertension and incident end-stage renal disease in patients with non-dialysis chronic kidney disease: results from the C-STRIDE Study

Qin Wang<sup>1</sup>, Yu Wang<sup>1\*</sup> , Jinwei Wang<sup>1</sup>, Luxia Zhang<sup>1,2</sup>, Ming-hui Zhao<sup>1,3</sup> and the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)

**Correction to: *J Transl Med* (2020) 18:238**

<https://doi.org/10.1186/s12967-020-02413-w>

After publication of the original article [1], the authors identified errors in Tables 1 and 2. The correct tables are given below.

The original article has been corrected.

---

The original article can be found online at <https://doi.org/10.1186/s12967-020-02413-w>.

\*Correspondence: [ddwangyu@sina.com](mailto:ddwangyu@sina.com)

<sup>1</sup> Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, National Health and Family Planning Commission of the People's Republic of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China  
Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Table 1 Baseline characteristic of participants according to different BP patterns diagnosed by criterion A**

	Total (N = 1714)	NT (N = 672)	WCH (N = 81)	MH (N + (N = 529)	SH (N = 432)	P
Age (years)	48.9 ± 13.8	46.7 ± 14.4	53.1 ± 14.4 <sup>a</sup>	49.9 ± 12.8 <sup>ab</sup>	50.0 ± 13.3 <sup>ab</sup>	< 0.001
Male, n (%)	974 (56.8%)	321 (47.8%)	38 (46.9%)	318 (60.1%) <sup>ab</sup>	297 (68.8%) <sup>abc</sup>	< 0.001
BMI (kg/m <sup>2</sup> )	24.6 ± 3.9	23.9 ± 3.6	25.0 ± 4.0 <sup>a</sup>	24.8 ± 3.8 <sup>a</sup>	25.6 ± 4.1 <sup>ac</sup>	< 0.001
Smokers, n (%)	623 (36.8%)	188 (28.2%)	24 (30.8%)	213 (40.7%) <sup>a</sup>	198 (46.7%) <sup>abc</sup>	< 0.001
DM, n (%)	366 (24.7%)	94 (16.5%)	18 (26.1%) <sup>a</sup>	123 (26.9%) <sup>a</sup>	131 (34.2%) <sup>abc</sup>	< 0.001
CVD history, n (%)	155 (9.0%)	41 (6.1%)	12 (14.8%)	55 (10.4%)	47 (10.9%)	0.004
Anti-hypertension, n (%) treatment	1245 (76.7%)	380 (61.8%)	66 (85.7%) <sup>a</sup>	422 (81.8%) <sup>a</sup>	377 (90.8%) <sup>ac</sup>	< 0.001
Causes of CKD*						< 0.001
DKD	212 (12.4%)	35 (5.2%)	11 (13.6%) <sup>a</sup>	73 (13.8%) <sup>a</sup>	93 (21.5%) <sup>abc</sup>	
GN	1048 (61.1%)	489 (72.8%)	40 (49.4%) <sup>a</sup>	313 (59.2%) <sup>a</sup>	206 (47.7%) <sup>ac</sup>	
Others	442 (25.8%)	144 (21.4%)	29 (35.8%) <sup>a</sup>	140 (26.5%)	129 (29.9%) <sup>a</sup>	
ALB (g/L)	38.3 ± 7.4	38.7 ± 7.2	39.4 ± 5.2	38.2 ± 7.6	37.7 ± 7.9 <sup>a</sup>	0.1
FBG (mmol/L)	4.9 (4.4, 5.6)	4.8 (4.3, 5.4)	5.0 (4.5, 5.5)	4.9 (4.4, 5.7) <sup>a</sup>	5.0 (4.5, 5.9) <sup>a</sup>	0.004
HGB (g/L)	126.5 ± 22.4	127.7 ± 19.55	121.9 ± 22.2 <sup>a</sup>	126.3 ± 24.2	125.7 ± 24.5	0.1
TG (mmol/L)	1.8 (1.2, 2.5)	1.7 (1.2, 2.4)	1.8 (1.3, 2.4)	1.9 (1.3, 2.6) <sup>a</sup>	1.9 (1.3, 2.6) <sup>a</sup>	0.004
TC (mmol/L)	4.7 (3.9, 5.7)	4.7 (3.9, 5.7)	4.6 (3.8, 5.5)	4.7 (3.9, 5.6)	4.7 (3.9, 5.7)	0.8
HDLC (mmol/L)	1.1 (0.9, 1.3)	1.1 (0.9, 1.4)	1.0 (0.9, 1.3)	1.0 (0.9, 1.3) <sup>a</sup>	1.1 (0.9, 1.2) <sup>a</sup>	0.001
LDLC (mmol/L)	2.6 (2.1, 3.2)	2.6 (2.1, 3.2)	2.6 (2.1, 3.2)	2.5 (2.1, 3.2)	2.7 (2.2, 3.3)	0.5
Cr (μmol/L)	98 (141, 198)	116.0 (80.0, 164.2)	153.0 (106.7, 218.4) <sup>a</sup>	151.0 (108.0, 204.5) <sup>a</sup>	167.0 (122.0, 243.2) <sup>ac</sup>	< 0.001
eGFR (mL/min/1.73 m <sup>2</sup> )	52.2 ± 30.1	62.9 ± 32.7	43.3 ± 24.3 <sup>a</sup>	48.2 ± 28.2 <sup>a</sup>	42.2 ± 23.3 <sup>ac</sup>	< 0.001
24 h-Upro (g/L)	1.0 (0.4, 2.4)	0.7 (0.3, 1.5)	1.0 (0.4, 2.9) <sup>a</sup>	1.1 (0.4, 2.5) <sup>a</sup>	1.8 (0.8, 3.5) <sup>abc</sup>	< 0.001
CKD stages, n (%)						< 0.001
1	256 (14.9%)	174 (25.9%)	5 (6.2%) <sup>a</sup>	55 (10.4%) <sup>a</sup>	22 (5.1%) <sup>ac</sup>	
2	305 (17.8%)	144 (21.4%)	11 (13.6%)	90 (17.0%)	60 (13.9%) <sup>a</sup>	
3	676 (39.5%)	228 (33.9%)	36 (44.4%)	220 (41.6%) <sup>a</sup>	192 (44.5%) <sup>a</sup>	
4	477 (27.8%)	126 (18.8%)	29 (35.8%) <sup>a</sup>	164 (31.0%) <sup>a</sup>	158 (36.6%) <sup>a</sup>	

\* The diagnosis was made mainly basing on medical history and clinical features, with only 578 patients having renal biopsy confirmation. Among them, 513 patients were diagnosed as GN. IgAN constituted the majority of GN group (54.2%), following by mesangial proliferative glomerulonephritis (32.2%) and membranous nephropathy (10.5%). Others group included hypertensive nephropathy, tubulointerstitial nephritis, and cause unknown etc

<sup>a</sup> P < 0.05 comparison with NT

<sup>b</sup> P < 0.05 comparison with WCH

<sup>c</sup> P < 0.05 comparison with MH

**Table 2 Clinical and ambulatory BP parameters of patients**

	Total	NT	WCH	MH	SH	P
Criterion A						
Clinic SBP (mmHg)	129.5 ± 17.3	118.6 ± 11.1	143.1 ± 13.4 <sup>a</sup>	124.9 ± 9.4 <sup>ab</sup>	149.4 ± 14.6 <sup>abc</sup>	<0.001
Clinic DBP (mmHg)	80.6 ± 10.4	74.8 ± 7.4	87.9 ± 9.1 <sup>a</sup>	78.6 ± 6.5 <sup>ab</sup>	90.8 ± 10.5 <sup>abc</sup>	<0.001
24 h-SBP (mmHg)	128.3 ± 17.0	114.5 ± 8.3	118.3 ± 7.3 <sup>a</sup>	134.8 ± 13.0 <sup>ab</sup>	143.6 ± 15.0 <sup>abc</sup>	<0.001
24 h-DBP (mmHg)	79.3 ± 10.8	70.9 ± 6.0	70.6 ± 5.9	84.5 ± 8.2 <sup>ab</sup>	87.4 ± 10.0 <sup>abc</sup>	<0.001
D-SBP (mmHg)	131.1 ± 17.0	116.7 ± 8.9	120.4 ± 7.5 <sup>a</sup>	136.4 ± 13.1 <sup>ab</sup>	145.1 ± 15.3 <sup>abc</sup>	<0.001
D-DBP (mmHg)	80.7 ± 11.0	72.6 ± 6.3	72.3 ± 6.3	85.8 ± 8.5 <sup>ab</sup>	88.6 ± 10.5 <sup>abc</sup>	<0.001
N-SBP (mmHg)	123.6 ± 18.7	109.6 ± 10.0	113.9 ± 10.5 <sup>a</sup>	130.4 ± 15.1 <sup>ab</sup>	138.9 ± 17.7 <sup>abc</sup>	<0.001
N-DBP (mmHg)	75.4 ± 12.5	66.7 ± 7.5	66.6 ± 9.3	80.6 ± 11.1 <sup>ab</sup>	84.1 ± 11.1 <sup>abc</sup>	<0.001
Criterion B						
Clinic SBP (mmHg)	129.5 ± 17.3	113.4 ± 9.7	131.6 ± 12.0 <sup>a</sup>	117.4 ± 8.9 <sup>ab</sup>	139.1 ± 15.9 <sup>abc</sup>	<0.001
Clinic DBP (mmHg)	80.6 ± 10.4	70.7 ± 6.2	83.4 ± 7.0 <sup>a</sup>	73.0 ± 5.5 <sup>ab</sup>	86.2 ± 9.5 <sup>abc</sup>	<0.001
24 h-SBP (mmHg)	128.3 ± 17.0	112.0 ± 8.3	116.7 ± 8.0 <sup>a</sup>	131.5 ± 12.3 <sup>ab</sup>	138.6 ± 15.2 <sup>abc</sup>	<0.001
24 h-DBP (mmHg)	79.3 ± 10.8	69.0 ± 5.9	71.7 ± 5.8 <sup>a</sup>	81.7 ± 8.1 <sup>ab</sup>	85.7 ± 9.5 <sup>abc</sup>	<0.001
D-SBP (mmHg)	131.1 ± 17.0	113.8 ± 8.3	117.7 ± 7.3 <sup>a</sup>	133.8 ± 12.2 <sup>ab</sup>	140.4 ± 15.1 <sup>abc</sup>	<0.001
D-DBP (mmHg)	80.7 ± 11.0	70.5 ± 5.9	72.6 ± 5.4 <sup>a</sup>	83.7 ± 8.0 <sup>ab</sup>	87.1 ± 9.6 <sup>abc</sup>	<0.001
N-SBP (mmHg)	123.6 ± 18.7	107.5 ± 10.8	113.5 ± 10.8 <sup>a</sup>	125.4 ± 14.4 <sup>ab</sup>	133.6 ± 17.8 <sup>abc</sup>	<0.001
N-DBP (mmHg)	75.4 ± 12.5	64.9 ± 7.5	69.0 ± 7.9 <sup>a</sup>	76.9 ± 9.7 <sup>ab</sup>	81.9 ± 10.7 <sup>abc</sup>	<0.001

24 h-SBP 24-hour average ambulatory systolic blood pressure, 24 h-DBP 24-hour average ambulatory diastolic blood pressure, D-SBP daytime systolic blood pressure, D-DBP daytime diastolic blood pressure, N-SBP nighttime systolic blood pressure, N-DBP nighttime diastolic blood pressure

#### Author details

<sup>1</sup> Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, National Health and Family Planning Commission of the People's Republic of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China. <sup>2</sup> Center for Data Science in Health and Medicine, Peking University, Beijing, China. <sup>3</sup> Peking-Tsinghua Center for Life Sciences, Beijing, China.

#### Reference

1. Wang Q, Wang Y, Wang J, Zhang L, Zhao M, the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). White-coat hypertension and incident end-stage renal disease in patients with non-dialysis chronic kidney disease: results from the C-STRIDE Study. *J Transl Med.* 2020;18:238. <https://doi.org/10.1186/s12967-020-02413-w>.

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 13 July 2020